What is the appropriate treatment for a complicated Candida (yeast) infection?

Treatment of Complicated Candida Infections

For complicated Candida infections, initiate systemic antifungal therapy immediately with echinocandins as first-line treatment (caspofungin 70 mg loading dose then 50 mg daily, micafungin 100-150 mg daily, or anidulafungin 200 mg loading then 100 mg daily), with treatment duration and approach determined by the specific site and severity of infection. 1, 2

Defining Complicated Candida Infections

Complicated infections include:

• Invasive candidiasis/candidemia - bloodstream infections requiring 2 weeks after blood culture clearance and symptom resolution 2
• Severe or recurrent vulvovaginal candidiasis - requiring 7-14 days of therapy rather than single-dose treatment 2
• Esophageal candidiasis - always requiring systemic therapy for 14-21 days 2
• Moderate-to-severe oropharyngeal candidiasis - particularly in immunocompromised patients 2
• CNS infections - requiring amphotericin B-based regimens 2
• Endocarditis, osteomyelitis, and deep-seated infections - requiring prolonged therapy and often surgical intervention 2
• Infections with resistant species (C. glabrata, C. krusei, C. auris) 1, 2

Site-Specific Treatment Algorithms

Candidemia and Invasive Candidiasis

Initial therapy:

• Echinocandins are preferred for all non-neutropenic patients, including critically ill ICU patients 1, 2
• Fluconazole 800 mg loading then 400 mg daily is acceptable only if: patient is not critically ill, no recent azole exposure, and local resistance rates <5% 2
• Remove central venous catheters - this is mandatory, not optional 2

Duration: Minimum 2 weeks after blood culture clearance AND resolution of all attributable symptoms 2

Step-down therapy: Transition to fluconazole 400-800 mg daily once clinically stable, blood cultures cleared, and isolate confirmed susceptible 2

CNS Candidiasis (Meningitis, Brain Abscess)

Initial therapy:

• Liposomal amphotericin B 5 mg/kg daily (preferred over deoxycholate formulation) 2
• Alternative: Amphotericin B deoxycholate 1 mg/kg daily 2
• Consider adding flucytosine 25 mg/kg four times daily for salvage therapy, though toxicity is common 2

Step-down: Fluconazole 12 mg/kg (400-800 mg) daily for susceptible isolates after clinical response 2

Duration: Continue until complete resolution of symptoms, CSF abnormalities, and radiological findings 2

Critical action: Remove all infected CNS devices (shunts, drains) if possible 2

Esophageal Candidiasis

Initial therapy:

• Fluconazole 200-400 mg daily for 14-21 days (first-line) 2
• For patients unable to take oral therapy: IV fluconazole 400 mg daily OR echinocandin (micafungin 150 mg, caspofungin 70 mg load then 50 mg, or anidulafungin 200 mg daily) 2

Fluconazole-refractory disease:

• Itraconazole solution 200 mg daily OR voriconazole 200 mg twice daily for 14-21 days 2
• Alternative: Echinocandin for 14-21 days OR amphotericin B deoxycholate 0.3-0.7 mg/kg daily for 21 days 2

Recurrent infections: Chronic suppression with fluconazole 100-200 mg three times weekly 2

Oropharyngeal Candidiasis

Mild disease:

• Clotrimazole troches 10 mg five times daily for 7-14 days 2
• Alternative: Nystatin suspension 4-6 mL four times daily 2

Moderate-to-severe disease:

• Fluconazole 100-200 mg daily for 7-14 days 2

Fluconazole-refractory:

• Itraconazole solution 200 mg daily OR posaconazole suspension 400 mg twice daily for 3 days then 400 mg daily (up to 28 days) 2
• For truly refractory cases: IV echinocandin OR amphotericin B deoxycholate 0.3 mg/kg daily 2

Complicated Vulvovaginal Candidiasis

Severe or recurrent infections:

• Fluconazole 150 mg every 72 hours for 3 doses (days 1,4,7) 3
• Alternative: Topical azole therapy for 7-14 days (longer than uncomplicated) 3

New options (2023):

• Ibrexafungerp and oteseconazole now available, though their role compared to fluconazole remains unclear in absence of resistance or intolerance 1, 4

Urinary Tract Infections

Cystitis (fluconazole-susceptible):

• Fluconazole 200 mg daily for 2 weeks 2
• Remove urinary catheter if present 2

Cystitis (fluconazole-resistant C. glabrata):

• Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days OR flucytosine 25 mg/kg four times daily for 7-10 days 2

Pyelonephritis:

• Fluconazole 200-400 mg daily for 2 weeks (susceptible organisms) 2
• For resistant species: Amphotericin B 0.3-0.6 mg/kg daily for 1-7 days with or without flucytosine 2
• Eliminate urinary obstruction - mandatory 2

Endocarditis

Initial therapy:

• Liposomal amphotericin B 3-5 mg/kg daily with or without flucytosine 25 mg/kg four times daily 2
• Alternative: High-dose echinocandin (caspofungin 150 mg, micafungin 150 mg, or anidulafungin 200 mg daily) 2

Step-down: Fluconazole 400-800 mg daily for susceptible isolates after clinical stability and blood culture clearance 2

Surgical intervention: Valve replacement is recommended; continue therapy ≥6 weeks post-surgery 2

Prosthetic valve: Same regimen plus chronic suppression with fluconazole 400-800 mg daily 2

Intra-abdominal Candidiasis

Approach:

• Source control is mandatory - drainage and/or debridement 2
• Antifungal choice: Same as candidemia treatment 2
• Duration: Based on adequacy of source control and clinical response 2

Empiric therapy indications: Recent abdominal surgery, anastomotic leaks, or necrotizing pancreatitis with clinical sepsis 2

Species-Specific Considerations

C. glabrata (Fluconazole-Resistant)

• Echinocandin preferred 2
• Alternative: Amphotericin B formulations 2
• Avoid fluconazole unless susceptibility confirmed 2

C. krusei (Intrinsically Fluconazole-Resistant)

• Echinocandin OR amphotericin B formulations 2
• Never use fluconazole 2

C. auris (Multidrug-Resistant)

• Echinocandin first-line 1
• For osteomyelitis: Consider combination therapy (liposomal amphotericin B + echinocandin) during intensive phase 5
• Rezafungin (long-acting echinocandin) may facilitate outpatient management 1, 5
• Coordinate with infection control for isolation and environmental measures 1, 6

Critical Pitfalls to Avoid

1. Do not delay treatment - initiate antifungals immediately upon positive blood culture notification, before speciation 2, 7

2. Do not use fluconazole empirically in critically ill patients - echinocandins have superior outcomes in ICU settings 2, 8

3. Do not forget source control - catheter removal for candidemia is non-negotiable; surgical intervention required for endocarditis, abscesses 2

4. Do not use echinocandins for CNS or ocular infections - poor penetration; use amphotericin B formulations 1, 2

5. Do not assume respiratory Candida requires treatment - usually represents colonization, not infection 2

6. Do not undertreated based on blood culture clearance alone - continue for full 2 weeks after clearance AND symptom resolution 2

Special Populations

Neonates with disseminated candidiasis:

• Amphotericin B deoxycholate 1 mg/kg daily (preferred) 2
• Fluconazole 12 mg/kg daily acceptable if no prior azole prophylaxis 2
• Echinocandins: Use with caution, limited to salvage situations 2
• Mandatory workup: Lumbar puncture, dilated retinal exam, imaging of genitourinary tract/liver/spleen 2

HIV patients with recurrent mucocutaneous infections:

• Antiretroviral therapy is essential to reduce recurrence 2
• Chronic suppression: Fluconazole 100-200 mg three times weekly 2

Emerging Therapies

The 2025 ECMM/ISHAM/ASM global guidance highlights new antifungals expanding treatment options 1:

• Rezafungin - long-acting echinocandin enabling weekly dosing for outpatient management 1, 5
• Ibrexafungerp and oteseconazole - novel agents for vulvovaginal candidiasis 1, 4

However, clinical experience remains limited, and these should be reserved for situations where standard therapies are unsuitable 1, 4.